- Conditions
- Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
- Interventions
- Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 187
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 149 more
Therapy Directory
Bevacizumab clinical trials
Directory of U.S. ClinicalTrials.gov public records that list Bevacizumab as a study intervention. Browse Bevacizumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
613
Shown on this page
12
Local indexed summaries
613
Local recruiting
97
Showing 1–12 of 613 matching trials for Bevacizumab.
Indexed local directory records.
Top conditions
Top sponsors
Top locations
Indexed official records
Open in full search- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Interventions
- Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, Ubamatamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 17 more
- Conditions
- Fibrolamellar Carcinoma, Hepatocellular Carcinoma, Malignant Solid Tumor, Pediatric Cancer, Pediatric Solid Tumor, Refractory Solid Tumor
- Interventions
- Atezolizumab, Bevacizumab, Cyclophosphamide, Sorafenib
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2037
- U.S. locations
- 2
- States / cities
- Germantown, Tennessee • Memphis, Tennessee
- Conditions
- Colorectal Cancer
- Interventions
- 5-Fluorouracil, Bevacizumab, Leucovorin, ONO-4578, Opdivo®, Oxaliplatin
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Los Angeles, California • Lone Tree, Colorado + 8 more
- Conditions
- Ovarian Cancer
- Interventions
- Bevacizumab, Cyclophosphamide, Pembrolizumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Bevacizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 604
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 426 more
- Conditions
- Ovarian Cancer, Ovarian Neoplasms
- Interventions
- Bevacizumab, Rescue Medications, Sacituzumab tirumotecan
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 6
- States / cities
- Miami Beach, Florida • Fort Wayne, Indiana • Covington, Louisiana + 3 more
- Conditions
- Cervical Cancer
- Interventions
- Bevacizumab, Carboplatin, Cisplatin, Paclitaxel, Pembrolizumab, Rescue Medications, Sacituzumab Tirumotecan
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,023 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 13
- States / cities
- Miami Beach, Florida • West Palm Beach, Florida • Shreveport, Louisiana + 10 more
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
- Interventions
- Bevacizumab, Cetuximab, Computed Tomography, Floxuridine, Fluorouracil, Implantation, Intrahepatic Infusion Procedure, Irinotecan, Leucovorin, Oxaliplatin, Panitumumab, Single Photon Emission Computed Tomography
- Biological · Procedure · Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2034
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 47 more
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Atezolizumab, Bevacizumab, Ipilimumab, Pumitamig
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Chicago, Illinois • Hackensack, New Jersey + 4 more
- Conditions
- Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms
- Interventions
- Bevacizumab, Carboplatin, Gemcitabine, MIRV, Paclitaxel, Pegylated liposomal doxorubicin (PLD), Sofetabart Mipitecan, Topotecan
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,080 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 66 more
- Conditions
- Colon Adenocarcinoma, Rectal Adenocarcinoma
- Interventions
- 5-Fluorouracil, Bevacizumab, Bevacizumab biosimilar, Calderasib, Cetuximab, Leucovorin/levofolinate calcium, Oxaliplatin
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Lone Tree, Colorado • Fort Myers, Florida + 19 more
About this Bevacizumab clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Bevacizumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
- How to narrow results
- Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Bevacizumab.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Bevacizumab.